CRIS Current Research Information System

POERIO, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.384
AS - Asia 1.182
EU - Europa 1.030
AF - Africa 90
SA - Sud America 53
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.373
VN - Vietnam 341
CN - Cina 292
SG - Singapore 269
GB - Regno Unito 257
SE - Svezia 170
DE - Germania 125
IT - Italia 111
JP - Giappone 83
FR - Francia 68
UA - Ucraina 66
IN - India 60
NL - Olanda 60
HK - Hong Kong 58
BR - Brasile 40
RU - Federazione Russa 40
IE - Irlanda 34
TG - Togo 33
CI - Costa d'Avorio 25
KR - Corea 20
FI - Finlandia 18
ZA - Sudafrica 17
CH - Svizzera 16
EE - Estonia 14
JO - Giordania 14
BG - Bulgaria 11
BE - Belgio 10
PL - Polonia 9
CA - Canada 8
GR - Grecia 8
IR - Iran 7
PH - Filippine 7
BD - Bangladesh 6
AR - Argentina 5
ES - Italia 5
SC - Seychelles 5
TR - Turchia 5
CL - Cile 4
NG - Nigeria 4
EC - Ecuador 3
TH - Thailandia 3
TW - Taiwan 3
AT - Austria 2
IQ - Iraq 2
KE - Kenya 2
MA - Marocco 2
MX - Messico 2
MY - Malesia 2
PK - Pakistan 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ET - Etiopia 1
ID - Indonesia 1
IL - Israele 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.740
Salva come PNG Salva come JPEG
Città #
Southend 216
Singapore 190
Chandler 180
Ashburn 135
Fairfield 108
Tokyo 74
Woodbridge 70
Houston 64
Wilmington 60
Dong Ket 59
Ho Chi Minh City 59
Seattle 57
Ann Arbor 56
Hefei 54
Hong Kong 50
San Jose 49
Hanoi 46
Jacksonville 44
Dallas 43
Princeton 39
Cambridge 35
Beijing 34
Dublin 34
Lomé 33
Santa Clara 31
Boardman 28
New York 27
Abidjan 24
Turin 22
Falls Church 20
Nanjing 20
Westminster 19
Padova 18
Helsinki 17
Lauterbourg 16
Seoul 16
Munich 15
Amman 14
Bern 14
Los Angeles 14
Berlin 12
Da Nang 12
Falkenstein 12
Jinan 12
Buffalo 11
Sofia 11
Brussels 10
Haiphong 9
Warsaw 9
Saint Petersburg 8
Changsha 7
Hangzhou 7
Jiaxing 7
Milan 7
Nanchang 7
San Diego 7
Taizhou 7
Bengaluru 6
Frankfurt am Main 6
Orem 6
Shenyang 6
Bremen 5
Des Moines 5
Guangzhou 5
Hebei 5
Medford 5
Phoenix 5
Pune 5
Tianjin 5
Zhengzhou 5
Bologna 4
Chengdu 4
Chiyoda-ku 4
Dearborn 4
Florence 4
Mahé 4
Mülheim 4
Washington 4
Abeokuta 3
Amsterdam 3
Atlanta 3
Boston 3
Can Tho 3
Chandigarh 3
Chicago 3
Haikou 3
Hamamatsu 3
Istanbul 3
Johannesburg 3
London 3
Mumbai 3
Ningbo 3
Qingdao 3
Rome 3
San Venanzo 3
Shanghai 3
Stockholm 3
São Paulo 3
Verona 3
Wuhan 3
Totale 2.426
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 300
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 242
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 205
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 186
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 179
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 157
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 103
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 101
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 93
null 85
null 77
null 57
Totale 3.809
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021163 0 0 0 0 0 0 0 0 0 14 20 129
2021/2022444 51 6 34 46 36 28 9 44 12 29 78 71
2022/2023587 72 116 31 70 36 45 14 24 94 14 50 21
2023/2024211 5 21 5 18 12 90 23 15 2 3 12 5
2024/2025457 13 56 32 36 58 38 27 19 1 65 25 87
2025/2026958 79 83 126 59 149 66 93 20 218 65 0 0
Totale 3.809